CN104350048B - 5-[5-苯基-4-(吡啶-2-基甲氨基)喹唑啉-2-基]吡啶-3-磺酰胺的氨基磷酸前药 - Google Patents

5-[5-苯基-4-(吡啶-2-基甲氨基)喹唑啉-2-基]吡啶-3-磺酰胺的氨基磷酸前药 Download PDF

Info

Publication number
CN104350048B
CN104350048B CN201380030478.2A CN201380030478A CN104350048B CN 104350048 B CN104350048 B CN 104350048B CN 201380030478 A CN201380030478 A CN 201380030478A CN 104350048 B CN104350048 B CN 104350048B
Authority
CN
China
Prior art keywords
compound
pyridin
compounds
phenyl
acetonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380030478.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104350048A (zh
Inventor
J.S.瓦里尔
N.D.亚达夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN104350048A publication Critical patent/CN104350048A/zh
Application granted granted Critical
Publication of CN104350048B publication Critical patent/CN104350048B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380030478.2A 2012-06-11 2013-06-10 5-[5-苯基-4-(吡啶-2-基甲氨基)喹唑啉-2-基]吡啶-3-磺酰胺的氨基磷酸前药 Active CN104350048B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11
US61/657913 2012-06-11
PCT/US2013/044882 WO2013188254A1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Publications (2)

Publication Number Publication Date
CN104350048A CN104350048A (zh) 2015-02-11
CN104350048B true CN104350048B (zh) 2016-12-07

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380030478.2A Active CN104350048B (zh) 2012-06-11 2013-06-10 5-[5-苯基-4-(吡啶-2-基甲氨基)喹唑啉-2-基]吡啶-3-磺酰胺的氨基磷酸前药

Country Status (34)

Country Link
US (1) US9238666B2 (cg-RX-API-DMAC7.html)
EP (1) EP2858987B1 (cg-RX-API-DMAC7.html)
JP (1) JP6234450B2 (cg-RX-API-DMAC7.html)
KR (1) KR102092984B1 (cg-RX-API-DMAC7.html)
CN (1) CN104350048B (cg-RX-API-DMAC7.html)
AR (1) AR091402A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013274619B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014030629B1 (cg-RX-API-DMAC7.html)
CA (1) CA2876359C (cg-RX-API-DMAC7.html)
CL (1) CL2014003361A1 (cg-RX-API-DMAC7.html)
CO (1) CO7160032A2 (cg-RX-API-DMAC7.html)
CY (1) CY1120432T1 (cg-RX-API-DMAC7.html)
DK (1) DK2858987T3 (cg-RX-API-DMAC7.html)
EA (1) EA024692B1 (cg-RX-API-DMAC7.html)
ES (1) ES2675314T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180815T8 (cg-RX-API-DMAC7.html)
HU (1) HUE039210T2 (cg-RX-API-DMAC7.html)
IL (1) IL236074A (cg-RX-API-DMAC7.html)
LT (1) LT2858987T (cg-RX-API-DMAC7.html)
MX (1) MX356699B (cg-RX-API-DMAC7.html)
MY (1) MY169219A (cg-RX-API-DMAC7.html)
NZ (1) NZ703632A (cg-RX-API-DMAC7.html)
PE (1) PE20150228A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502747B1 (cg-RX-API-DMAC7.html)
PL (1) PL2858987T3 (cg-RX-API-DMAC7.html)
PT (1) PT2858987T (cg-RX-API-DMAC7.html)
RS (1) RS57376B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201408076WA (cg-RX-API-DMAC7.html)
SI (1) SI2858987T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800369T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000499A1 (cg-RX-API-DMAC7.html)
TW (1) TWI571470B (cg-RX-API-DMAC7.html)
WO (1) WO2013188254A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500161B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9403834B2 (en) * 2013-03-11 2016-08-02 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN105008366B (zh) * 2013-03-11 2017-11-14 百时美施贵宝公司 作为钾离子通道抑制剂的吡咯并哒嗪类化合物
KR20180084049A (ko) * 2015-11-19 2018-07-24 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 제약 화합물의 아민 전구약물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190967A (zh) * 1995-07-13 1998-08-19 诺尔股份公司 杂环甲酰胺衍生物及其作为治疗剂的用途
CN101084209A (zh) * 2004-12-21 2007-12-05 德福根有限公司 具有Kv4离子通道活性的化合物
WO2011028741A1 (en) * 2009-09-03 2011-03-10 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP2016516691A (ja) * 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのイソキノリン
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190967A (zh) * 1995-07-13 1998-08-19 诺尔股份公司 杂环甲酰胺衍生物及其作为治疗剂的用途
CN101084209A (zh) * 2004-12-21 2007-12-05 德福根有限公司 具有Kv4离子通道活性的化合物
WO2011028741A1 (en) * 2009-09-03 2011-03-10 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
MX356699B (es) 2018-06-11
TW201402592A (zh) 2014-01-16
EP2858987A1 (en) 2015-04-15
PH12014502747A1 (en) 2015-02-02
AR091402A1 (es) 2015-02-04
AU2013274619A1 (en) 2015-01-29
CO7160032A2 (es) 2015-01-15
JP6234450B2 (ja) 2017-11-22
CA2876359A1 (en) 2013-12-19
PH12014502747B1 (en) 2015-02-02
RS57376B1 (sr) 2018-08-31
CN104350048A (zh) 2015-02-11
NZ703632A (en) 2016-01-29
JP2015521598A (ja) 2015-07-30
CY1120432T1 (el) 2019-07-10
BR112014030629A2 (pt) 2017-06-27
WO2013188254A1 (en) 2013-12-19
EA201492256A1 (ru) 2016-05-31
SI2858987T1 (en) 2018-06-29
KR20150023667A (ko) 2015-03-05
PL2858987T3 (pl) 2018-08-31
CL2014003361A1 (es) 2015-05-29
PT2858987T (pt) 2018-07-04
HRP20180815T8 (hr) 2019-02-08
US20150175641A1 (en) 2015-06-25
ZA201500161B (en) 2017-04-26
IL236074A0 (en) 2015-02-01
MY169219A (en) 2019-03-19
SMT201800369T1 (it) 2018-09-13
HRP20180815T1 (hr) 2018-06-29
DK2858987T3 (en) 2018-07-30
HK1203928A1 (en) 2015-11-06
MX2014014525A (es) 2015-02-24
SG11201408076WA (en) 2015-01-29
HUE039210T2 (hu) 2018-12-28
EA024692B1 (ru) 2016-10-31
LT2858987T (lt) 2018-07-10
PE20150228A1 (es) 2015-02-19
AU2013274619B2 (en) 2017-09-28
ES2675314T3 (es) 2018-07-10
TWI571470B (zh) 2017-02-21
KR102092984B1 (ko) 2020-03-24
US9238666B2 (en) 2016-01-19
BR112014030629B1 (pt) 2021-12-21
EP2858987B1 (en) 2018-04-25
IL236074A (en) 2016-08-31
CA2876359C (en) 2020-01-21
TN2014000499A1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
ES2750598T3 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
CN105008366B (zh) 作为钾离子通道抑制剂的吡咯并哒嗪类化合物
US9242966B2 (en) Phthalazines as potassium ion channel inhibitors
TWI571470B (zh) 磷醯胺酸前藥
CN105026399B (zh) 作为钾离子通道抑制剂的吡咯并三嗪类化合物
HK1203928B (en) Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide
JP2008521810A (ja) (2s)−1−[[(7r)−7−(3,4−ジクロロフェニル)−4,7−ジヒドロ−5−メチルピラゾロ[1,5]ピリミジン−6−イル]カルボニル]−2−(4−フルオロフェニル)ピロリジンの新規な結晶形の製造方法、該製造方法において製造される新規な安定な結晶形、および製剤
JP2024511617A (ja) 新規なインドールアミン-2,3-ジオキシゲナーゼ阻害剤、その製造方法、およびそれを含む医薬組成物
HK40018229B (en) Quinazolines as potassium ion channel inhibitors
HK40018229A (en) Quinazolines as potassium ion channel inhibitors
CN108383799A (zh) 抗肿瘤新药的合成方法及其药用盐和固体制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant